These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 16396776

  • 1. Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
    Lee C, Lin Y, Huang M, Lin C, Liu C, Chow J, Liu HE.
    Leuk Lymphoma; 2006 Mar; 47(3):521-9. PubMed ID: 16396776
    [Abstract] [Full Text] [Related]

  • 2. The optimal dose of arsenic trioxide induced opposite efficacy in autophagy between K562 cells and their initiating cells to eradicate human myelogenous leukemia.
    Guo Z, Meng M, Geng S, Du Z, Zheng Y, Yao J, Li Z, Han G, Lin H, Du G.
    J Ethnopharmacol; 2017 Jan 20; 196():29-38. PubMed ID: 27965050
    [Abstract] [Full Text] [Related]

  • 3. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I, Bailón E, Aguilera-Montilla N, Terol MJ, García-Marco JA, García-Pardo A.
    Oncotarget; 2015 Dec 29; 6(42):44832-48. PubMed ID: 26540567
    [Abstract] [Full Text] [Related]

  • 4. Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.
    Wang R, Xia L, Gabrilove J, Waxman S, Jing Y.
    Leukemia; 2013 Feb 29; 27(2):315-24. PubMed ID: 22751450
    [Abstract] [Full Text] [Related]

  • 5. Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1.
    Wang R, Liu C, Xia L, Zhao G, Gabrilove J, Waxman S, Jing Y.
    Clin Cancer Res; 2012 Dec 15; 18(24):6690-701. PubMed ID: 23082001
    [Abstract] [Full Text] [Related]

  • 6. Potentiation of arsenic trioxide cytotoxicity by Parthenolide and buthionine sulfoximine in murine and human leukemic cells.
    Duechler M, Stańczyk M, Czyz M, Stepnik M.
    Cancer Chemother Pharmacol; 2008 Apr 15; 61(5):727-37. PubMed ID: 17594095
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells.
    Kumar S, Yedjou CG, Tchounwou PB.
    J Exp Clin Cancer Res; 2014 May 16; 33(1):42. PubMed ID: 24887205
    [Abstract] [Full Text] [Related]

  • 9. The cytotoxicity of arsenic trioxide to normal hematopoietic progenitors and leukemic cells is dependent on their cell-cycle status.
    Huang MJ, Hsieh RK, Lin CP, Chang IY, Liu HJ.
    Leuk Lymphoma; 2002 Nov 16; 43(11):2191-9. PubMed ID: 12533046
    [Abstract] [Full Text] [Related]

  • 10. Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines.
    Ramos AM, Aller P.
    Biochem Pharmacol; 2008 May 15; 75(10):1912-23. PubMed ID: 18359480
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia.
    Aldoss I, Mark L, Vrona J, Ramezani L, Weitz I, Mohrbacher AM, Douer D.
    Ann Hematol; 2014 Nov 15; 93(11):1839-43. PubMed ID: 24906216
    [Abstract] [Full Text] [Related]

  • 14. Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
    Konig H, Härtel N, Schultheis B, Schatz M, Lorentz C, Melo JV, Hehlmann R, Hochhaus A, La Rosée P.
    Haematologica; 2007 Jun 15; 92(6):838-41. PubMed ID: 17550858
    [Abstract] [Full Text] [Related]

  • 15. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
    Chen P, Zhan W, Wang B, You P, Jin Q, Hou D, Wang X, You R, Zou H, Chen Y, Huang H.
    Exp Cell Res; 2019 Mar 15; 376(2):114-123. PubMed ID: 30763586
    [Abstract] [Full Text] [Related]

  • 16. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.
    Cholujova D, Bujnakova Z, Dutkova E, Hideshima T, Groen RW, Mitsiades CS, Richardson PG, Dorfman DM, Balaz P, Anderson KC, Jakubikova J.
    Br J Haematol; 2017 Dec 15; 179(5):756-771. PubMed ID: 29048129
    [Abstract] [Full Text] [Related]

  • 17. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins.
    Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M.
    Leukemia; 2002 Sep 15; 16(9):1713-24. PubMed ID: 12200686
    [Abstract] [Full Text] [Related]

  • 18. High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
    Noguera NI, Pelosi E, Angelini DF, Piredda ML, Guerrera G, Piras E, Battistini L, Massai L, Berardi A, Catalano G, Cicconi L, Castelli G, D'Angiò A, Pasquini L, Graziani G, Fioritoni G, Voso MT, Mastrangelo D, Testa U, Lo-Coco F.
    Oncotarget; 2017 May 16; 8(20):32550-32565. PubMed ID: 28427227
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old.
    Parmar S, Rundhaugen LM, Boehlke L, Riley M, Nabhan C, Raji A, Frater JL, Tallman MS.
    Leuk Res; 2004 Sep 16; 28(9):909-19. PubMed ID: 15234567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.